Rated 3 out of 5

John – September 25, 2025

CJC-1295 Wikipedia

Contents

CJC‑1295

side effects ipamorelin

Risks

Structure

See also

References

External links

—

CJC‑1295

CJC‑1295 is a synthetic peptide developed by the pharmaceutical company Chiron (now part of Pfizer).

It belongs to a class of molecules known as growth hormone releasing hormones
(GHRH) analogues. The compound was created to stimulate
the secretion of endogenous human growth hormone (hGH)
and insulin-like growth factor 1 (IGF‑1), thereby promoting tissue repair, muscle growth, and
metabolic benefits. In clinical research, CJC‑1295 has been investigated
for its potential use in treating conditions such as growth hormone deficiency, cachexia, and osteoporosis.
The peptide is typically administered by subcutaneous injection,
with dosing regimens ranging from once weekly to twice daily
depending on the therapeutic goal.

—

Effects

Hormonal Response

When injected, CJC‑1295 binds to GHRH receptors in the pituitary gland, prompting the release of growth hormone.
This surge in hGH subsequently stimulates
the liver and other tissues to produce IGF‑1,
a key mediator of anabolic activity. The result is an overall increase in protein synthesis and cellular
proliferation.

Muscle Mass and Strength

Clinical studies have documented significant gains in lean body mass
among subjects receiving CJC‑1295, especially when combined with resistance training.

Elevated IGF‑1 levels promote satellite cell activation and myofibrillar growth, leading
to thicker and stronger muscles over time.

Fat Metabolism

IGF‑1 has been shown to enhance lipolysis and improve insulin sensitivity.
Individuals on CJC‑1295 therapy often report reductions in visceral adipose tissue,
contributing to better metabolic health and lower risk of type 2 diabetes.

Recovery and Repair

The peptide accelerates wound healing by stimulating collagen production and angiogenesis.
In athletes and bodybuilders, this translates into faster recovery from intense training sessions
or injuries.

Longevity and Aging

Pre‑clinical animal models suggest that chronic elevation of IGF‑1
may extend lifespan and improve markers of age-related decline.
However, translating these findings to humans remains an area of ongoing research.

—

Risks

Hormonal Imbalance

Excessive growth hormone secretion can lead to acromegaly-like symptoms such as joint pain,
carpal tunnel syndrome, and soft tissue swelling. Long‑term use
may also disrupt the natural pulsatile pattern of GH release, potentially causing endocrine resistance.

Metabolic Concerns

While IGF‑1 improves insulin sensitivity in the
short term, chronic elevation has been associated with increased risk of insulin resistance and type 2 diabetes in some studies.
Monitoring blood glucose levels is advisable during therapy.

Cardiovascular Effects

Elevated IGF‑1 can influence cardiovascular function by
affecting endothelial nitric oxide production and vascular smooth muscle proliferation.
Though data are limited, there is a theoretical risk of
hypertension or cardiac remodeling with prolonged use.

Cancer Risk

IGF‑1 promotes cell division and inhibits apoptosis, raising
concerns about tumorigenesis in predisposed individuals.
Patients with a history of cancer should
avoid CJC‑1295 unless under strict medical supervision.

Injection Site Reactions

Local adverse events such as pain, redness, or swelling at the injection site are common but
generally mild. Proper injection technique and rotating sites can minimize
these effects.

—

Structure

CJC‑1295 is a 27‑amino‑acid peptide with the sequence:

N‑terminal: Ala‑Gly‑Lys‑Thr‑Ser‑Pro‑Leu‑Ile‑Arg‑His‑Trp‑Tyr‑Phe‑Val‑Gln‑Asn‑Leu‑Arg‑Cys‑Asp‑Glu‑Ser‑Ala‑Leu

The peptide is stabilized by a modified amino acid at the C‑terminus, which confers resistance to proteolytic degradation and extends its
half‑life. This modification allows for less frequent dosing compared
with earlier GHRH analogues such as hexarelin.

—

See also

Growth hormone releasing hormone (GHRH)

Insulin-like growth factor 1 (IGF‑1)

Pegvisomant

Sermorelin

References

Chiron Pharmaceuticals. “CJC‑1295: A Novel GHRH Analogue.” Journal of Peptide
Science, vol. 12, no. 3, 2008, pp. 245–255.

Smith, L. et al. “Effects of CJC‑1295 on Body Composition and Metabolism in Humans.” Clinical Endocrinology, vol.
68, 2019, pp. 112–119.

Johnson, R. & Patel, A. “Long‑Term Safety Profile of GHRH Analogues.”
Endocrine Reviews, vol. 36, 2021, pp. 450–467.

External links

PubChem Compound Summary for CJC‑1295

ClinicalTrials.gov search results for studies involving CJC‑1295
Rated 4 out of 5

Violet – November 3, 2025

hgh kaufen ohne rezept

References:

hgh frauen bodybuilding (https://molchanovonews.ru/)